CoreCivic’s Third Annual ESG Report Shows Steadfast Commitment to Reducing Recidivism, Focus on Keeping People Safe and Front Line Resiliency Amid Pandemic

NEXT STORY
Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress
PREV STORY
Apellis to Present Long-Term Pegcetacoplan Data in PNH at the European Hematology Association Virtual Congress
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Preliminary Results from NexImmune’s Phase 1/2 Trial of NEXI-001 in AML Presented at 62nd ASH Annual Meeting and Exposition

author_avatar
NASDAQ Market News

Outlook on the Worldwide Oligonucleotide Synthesis Market, 2019 to 2024 – Emerging Asian Markets Present Lucrative Opportunities

author_avatar
NASDAQ Market News

Market Research Finds 99% Of US Clinical Cardiologists Surveyed Report a High Unmet Need for New Innovative Drug Treatments for Early Cardiogenic Shock Patients (ECS) as Windtree Therapeutics Prepares for Clinical Results from its Istaroxime ECS Study

author_avatar
NASDAQ Market News